Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
1,983.00    -0.50 (-0.03%)
Bid:
1,978.50
Ask:
1,979.50
Spread: 1.00 (0.051%)
Market Cap: £79.45b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Director/PDMR Shareholding

5 May 2026 15:30

RNS Number : 0889D
GSK PLC
05 May 2026
 

GSK plc (the 'Company')

 

2026 Award under the Deferred Investment Award Programme

Notional Award

 

On 1 May 2026, the Company granted an award over notional Ordinary Shares to Roanne Parry, a Person Discharging Managerial Responsibilities ('PDMR'), under the GlaxoSmithKline Deferred Investment Award programme. The award has been granted upon Ms Parry joining GSK as Chief People Officer and a newly appointed Executive Committee member.

 

Under the programme, awards are made over notional Ordinary Shares with vesting over a specified period to provide long-term alignment with shareholders. Vesting is subject to the PDMR not having served the Company notice or having been terminated by the Company for cause. Dividends will accrue on the award during the vesting period. On vesting, the award will be paid in cash. The award will vest in two increments: 34.22% of the award will vest on 31 August 2028 and 65.78% of the award will vest on 31 August 2029.

 

Executive Directors are not eligible to receive awards under the programme.

 

Transaction notification

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Roanne Parry

b)

Position/status

Chief People Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

A restricted award of notional Ordinary Shares under the Company's Deferred Investment Award programme.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£19.01

35,507.628

d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

e)

Date of the transaction

2026-05-01

f)

Place of the transaction

 

N/A

 

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

79 New Oxford Street

London

WC1A 1DG

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHSSAFFIEMSEFI
Date   Source Headline
18th Jan 20245:00 pmRNSHolding(s) in Company
17th Jan 20243:30 pmRNSDirector/PDMR Shareholding
17th Jan 20247:00 amRNSGSK completes sale of shares in Haleon plc
16th Jan 20244:40 pmRNSGSK announces intention to sell shares in Haleon
16th Jan 20243:30 pmRNSDirector/PDMR Shareholding
10th Jan 20247:00 amRNSNucala approved in China for use in severe asthma
9th Jan 20247:00 amRNSGSK enters agreement to acquire Aiolos Bio
2nd Jan 20243:00 pmRNSTotal Voting Rights
21st Dec 20233:30 pmRNSDirector/PDMR Shareholding
20th Dec 20234:44 pmRNSPublication of EMTN Suppl.Prospcts
18th Dec 20237:00 amRNSJemperli plus Zejula Trial Meets Endpoint
13th Dec 20233:30 pmRNSDirector/PDMR Shareholding
12th Dec 20237:00 amRNSJapan accepts Arexvy filing for at risk adults
11th Dec 20237:00 amRNSJemperli plus chemotherapy EU authorisation
4th Dec 20233:02 pmRNSGSK publishes provisional 2024 dividend dates
1st Dec 20233:00 pmRNSTotal Voting Rights
30th Nov 20239:00 amRNSBlock Listing Application
29th Nov 20233:23 pmRNSHolding(s) in Company
27th Nov 20237:00 amRNSGSK announces positive DREAMM-7 headline results
21st Nov 20233:30 pmRNSDirector/PDMR Shareholding
15th Nov 20233:00 pmRNSBlock listing Interim Review
13th Nov 20233:30 pmRNSDirector/PDMR Shareholding
13th Nov 20237:00 amRNSGSK receives positive CHMP opinion for momelotinib
1st Nov 20233:00 pmRNSTotal Voting Rights
1st Nov 20237:00 amRNS3rd Quarter Results
30th Oct 20237:00 amRNSJemperli trial meets overall survival endpoint
26th Oct 20237:00 amRNSNMPA approves Vocabria+Rekambys in China
25th Oct 20233:30 pmRNSDirector/PDMR Shareholding
25th Oct 20237:00 amRNSNew data for Arexvy, GSK’s RSV vaccine
20th Oct 20233:30 pmRNSDirector/PDMR Shareholding
18th Oct 20233:30 pmRNSDirector/PDMR Shareholding
17th Oct 20233:30 pmRNSDirector/PDMR Shareholding
16th Oct 20237:00 amRNSJemperli plus chemotherapy positive CHMP opinion
13th Oct 20233:30 pmRNSDirector/PDMR Shareholding
12th Oct 20233:30 pmRNSDirector/PDMR Shareholding
11th Oct 20237:00 amRNSZantac (ranitidine) litigation
10th Oct 202311:00 amRNSHolding(s) in Company
9th Oct 20237:00 amRNSGSK and Zhifei announce vaccine partnership
6th Oct 20237:00 amRNSGSK completes sale of shares in Haleon plc
5th Oct 20234:46 pmRNSGSK announces intention to sell shares in Haleon
2nd Oct 20233:00 pmRNSTotal Voting Rights
27th Sep 20233:00 pmRNSDirectorate Change
25th Sep 20237:00 amRNSGSK RSV vaccine for older adults approved in Japan
21st Sep 20233:30 pmRNSDirector/PDMR Shareholding
19th Sep 20237:00 amRNSApretude for PrEP receives EMA approval
18th Sep 20237:00 amRNSFDA approves Ojjaara (momelotinib)
13th Sep 20233:30 pmRNSDirector/PDMR Shareholding
11th Sep 20233:30 pmRNSDirector/PDMR Shareholding
11th Sep 20237:00 amRNSMomelotinib filing accepted in Japan
1st Sep 20233:00 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.